CytomX Therapeutics (CTMX) Competitors $3.74 +0.54 (+16.88%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$3.77 +0.03 (+0.80%) As of 10/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. ETNB, SRPT, OCUL, DYN, ANIP, VERA, TLRY, TWST, COGT, and GPCRShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include 89BIO (ETNB), Sarepta Therapeutics (SRPT), Ocular Therapeutix (OCUL), Dyne Therapeutics (DYN), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Tilray Brands (TLRY), Twist Bioscience (TWST), Cogent Biosciences (COGT), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors 89BIO Sarepta Therapeutics Ocular Therapeutix Dyne Therapeutics ANI Pharmaceuticals Vera Therapeutics Tilray Brands Twist Bioscience Cogent Biosciences Structure Therapeutics 89BIO (NASDAQ:ETNB) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings. Do analysts prefer ETNB or CTMX? 89BIO presently has a consensus target price of $25.81, suggesting a potential upside of 74.41%. CytomX Therapeutics has a consensus target price of $5.42, suggesting a potential upside of 44.83%. Given 89BIO's higher possible upside, research analysts plainly believe 89BIO is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89BIO 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.40CytomX Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor ETNB or CTMX? In the previous week, CytomX Therapeutics had 5 more articles in the media than 89BIO. MarketBeat recorded 6 mentions for CytomX Therapeutics and 1 mentions for 89BIO. 89BIO's average media sentiment score of 0.50 beat CytomX Therapeutics' score of 0.27 indicating that 89BIO is being referred to more favorably in the media. Company Overall Sentiment 89BIO Positive CytomX Therapeutics Neutral Which has stronger earnings and valuation, ETNB or CTMX? CytomX Therapeutics has higher revenue and earnings than 89BIO. 89BIO is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89BION/AN/A-$367.08M-$3.61-4.10CytomX Therapeutics$138.10M4.47$31.87M$0.566.68 Is ETNB or CTMX more profitable? CytomX Therapeutics has a net margin of 34.04% compared to 89BIO's net margin of 0.00%. CytomX Therapeutics' return on equity of 158.70% beat 89BIO's return on equity.Company Net Margins Return on Equity Return on Assets 89BION/A -94.48% -80.92% CytomX Therapeutics 34.04%158.70%36.04% Do insiders and institutionals hold more shares of ETNB or CTMX? 67.8% of CytomX Therapeutics shares are owned by institutional investors. 2.8% of 89BIO shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, ETNB or CTMX? 89BIO has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. SummaryCytomX Therapeutics beats 89BIO on 13 of the 15 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$527.72M$3.46B$6.14B$10.55BDividend YieldN/A2.27%5.72%4.84%P/E Ratio6.6823.3929.4727.34Price / Sales4.47488.49580.96227.67Price / Cash8.8445.2825.8230.35Price / Book-374.0010.6112.526.69Net Income$31.87M-$52.56M$3.32B$276.46M7 Day Performance9.36%3.95%1.81%-0.08%1 Month Performance88.89%16.10%8.81%3.93%1 Year Performance222.41%15.08%64.29%33.89% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.3721 of 5 stars$3.74+16.9%$5.42+44.8%+216.9%$527.72M$138.10M6.68170News CoverageETNB89BIO2.9408 of 5 stars$14.80flat$25.81+74.4%+77.2%$2.19BN/A-4.1040Short Interest ↓SRPTSarepta Therapeutics4.5976 of 5 stars$21.96-0.7%$34.42+56.7%-81.9%$2.16B$1.90B-25.241,372OCULOcular Therapeutix4.3174 of 5 stars$11.85+0.6%$22.63+90.9%+7.5%$2.05B$63.72M-9.26230Analyst RevisionDYNDyne Therapeutics3.3321 of 5 stars$14.03-0.1%$34.07+142.8%-51.5%$2.00BN/A-3.63100ANIPANI Pharmaceuticals3.8027 of 5 stars$88.61-1.3%$99.14+11.9%+57.7%$1.95B$614.38M-115.08600VERAVera Therapeutics2.6998 of 5 stars$30.49+1.3%$63.00+106.6%-26.6%$1.92BN/A-8.5240TLRYTilray Brands3.3248 of 5 stars$1.69-1.7%$2.00+18.3%-1.3%$1.89B$821.31M-0.742,842TWSTTwist Bioscience3.8575 of 5 stars$30.14-3.4%$48.50+60.9%-30.2%$1.88B$312.97M-20.79990COGTCogent Biosciences1.9989 of 5 stars$16.20-0.4%$20.00+23.5%+36.3%$1.85BN/A-9.1080News CoverageGap UpGPCRStructure Therapeutics3.292 of 5 stars$30.19+0.4%$68.67+127.4%-29.4%$1.73BN/A-28.75136 Related Companies and Tools Related Companies 89BIO Competitors Sarepta Therapeutics Competitors Ocular Therapeutix Competitors Dyne Therapeutics Competitors ANI Pharmaceuticals Competitors Vera Therapeutics Competitors Tilray Brands Competitors Twist Bioscience Competitors Cogent Biosciences Competitors Structure Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTMX Stock Alerts